Singapore, April 11 -- Novartis, a leading global innovative medicines company, has announced a planned$23 billioninvestment over 5 years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made inthe United States.

This commitment enables Novartis to expand on its current manufacturing, research and technology presence across the country with 10 facilities, including 7 brand new facilities, creating nearly 1,000 new jobs at Novartis and approximately 4,000 additional US jobs.

The production capacity will cover both active pharmaceutical ingredients (API) and biologics drug substance, as well as secondary production and packaging.

Over the next 5 years, Novartis will establish 1 biomedical research i...